Extraintestinal Manifestations of Inflammatory Bowel Disease

  • Giacomo C. Sturniolo
  • Michela Barollo
  • Renata D’Incà


Inflammatory Bowel Disease Ulcerative Colitis Primary Sclerosing Cholangitis Human Leukocyte Antigen Class Ursodeoxycholic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Das KM (1999) Relationship of extraintestinal involvements in inflammatory bowel disease. Dig Dis Sci 44(1):1–13PubMedCrossRefGoogle Scholar
  2. 2.
    Bernstein CN, Blanchard JF, Rawsthorne P et al (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96(4):1116–1122PubMedCrossRefGoogle Scholar
  3. 3.
    Snook JA, de Silva HJ, Jewell DP (1989) The association of autoimmune disorders with inflammatory bowel disease. Quart J Med 269:835–840Google Scholar
  4. 4.
    Brandtzaeg P, Halstensen TS, Kett K (1992) Immunopathology of inflammatory bowel disease. In: MacDermott RP, Stenson WF (eds) Inflammatory bowel disease, current topics in gastroenterology. Elsevier, London, pp 95–136Google Scholar
  5. 5.
    Padolsky DK (1991) Inflammatory bowel disease: Part 1. N Engl J Med 325:928–937CrossRefGoogle Scholar
  6. 6.
    Sartor RB (1995) Microbial factors in the pathogenesis of Crohn’s disease, ulcerative colitis and experimental intestinal inflammation. Inflammatory bowel disease. In: Kirsner JB, Shorter RJ (eds) Lea & Febiger, Philadelphia, pp 96–124Google Scholar
  7. 7.
    MacDermott RP, Elson CO (1991) Mucosal immunology I. Gastroenterol Clin North Am 20:397–627Google Scholar
  8. 8.
    Breban M, Hammer RE, Richardson JA et al (1993) Transfer of the inflammatory disease of HLA B27 transgenic rats by bone marrow engraftment. J Exp Med 178:1607–1616PubMedCrossRefGoogle Scholar
  9. 9.
    Taurog JD, Richardson JA, Croft JT et al (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364PubMedCrossRefGoogle Scholar
  10. 10.
    Mizoguchi A, Mizoguchi E, Chiba C et al (1996) Cytokine imbalance and autoantibody production in T cell receptor-a mutant mice with inflammatory bowel disease. J Exp Med 183:847–856PubMedCrossRefGoogle Scholar
  11. 11.
    Chapman RW, Cottone M, Selby WS et al (1986) Serum autoantibodies in ulcerative colitis and primary sclerosing cholangitis. Gut 27:86–91PubMedGoogle Scholar
  12. 12.
    Tan EM (1991) Autoantibodies in pathology and cell biology. Cell 67:841–842PubMedCrossRefGoogle Scholar
  13. 13.
    Satsagi J, Grootscholten C, Holt H et al (1996) Clinical pattern of familial inflammatory bowel disease. Gut 38:738–741Google Scholar
  14. 14.
    Rump JA, Scholmerich J, Gross V et al (1990) A new type of perinuclear anti-neutrophil cytoplasmatic antibody (p-ANCA) in ulcerative colitis but not in Crohn’s disease. Immunobiology 181:406–413PubMedGoogle Scholar
  15. 15.
    Hoffenberg J, Fidanza S, Sauaia A (1999) Serologic testing for inflammatory bowel disease. J Pediatr 134:447–452PubMedCrossRefGoogle Scholar
  16. 16.
    Lawrance IC, Murray K, Hall A et al (2004) A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 99:2186–2194PubMedCrossRefGoogle Scholar
  17. 17.
    Satsagi J, Grootscholten C, Holt H et al (1996) Clinical pattern of familial inflammatory bowel disease. Gut 38:738–741Google Scholar
  18. 18.
    Seibold F, Slametschka D, Gregor M et al (1992) Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 107:532–536Google Scholar
  19. 19.
    Greenstein AJ, Janovitz HD, Sachar DB (1976) The extraintestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine 5:401–412Google Scholar
  20. 20.
    Reinshagen M, Von Tirpitz C (2003) Osteoporosis and other extraintestinal symptoms and complications of inflammatory bowel diseases. Dig Dis 21:138–145PubMedCrossRefGoogle Scholar
  21. 21.
    Orchard TR (2001) Arthritis associated with inflammatory bowel disease. In: Bayless TM, Hanauer SB (eds) Advanced therapy of inflammatory bowel disease. Decker, Hamilton, London, pp 279–288Google Scholar
  22. 22.
    Orchard TR, Wordsworth BP, Jewell DP (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42:387–391PubMedCrossRefGoogle Scholar
  23. 23.
    Punzi L, Podswiadek M, D’Incà R et al (2003) Serum human cartilage glycoprotein 39 as a marker of arthritis associated with inflammatory bowel disease. Ann Rheum Dis 62(12):1224–1226PubMedCrossRefGoogle Scholar
  24. 24.
    De Vos M, De Keyser F, Mielants H et al (1998) Review article: bone and joint disease in inflammatory bowel disease. Aliment Pharmacol Ther 12:397–404PubMedCrossRefGoogle Scholar
  25. 25.
    Podswiadek M, Punzi L, Stramare R et al (2004) The prevalence of radiographic sacroiliitis in patients affected by inflammatory bowel disease with inflammatory low back pain. Reumatismo 56(2):110–113PubMedGoogle Scholar
  26. 26.
    De Vos M (2004) Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 20[Suppl 4]:36–42PubMedCrossRefGoogle Scholar
  27. 27.
    Adler G, Reinshagen M (2003) Extraintestinale Manifestationen. Z Gastroenterol 41:54–61PubMedCrossRefGoogle Scholar
  28. 28.
    Sieper J, Braun J (2001) New treatment options in ankylosing spondylitis: a role for anti-TNFa therapy. Ann Rheum Dis 60(Suppl 3):58–61Google Scholar
  29. 29.
    Compston JE (1995) Review article: osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmachol Ther 9:237–250CrossRefGoogle Scholar
  30. 30.
    Bernstein CN, Leslie WD (2004) Review article: osteoporosis and inflammatory bowel disease. Aliment Pharmacol Ther 19:941–952PubMedCrossRefGoogle Scholar
  31. 31.
    Schulte C, Dignass AU, Mann K et al (1998) Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 4(4):268–275PubMedCrossRefGoogle Scholar
  32. 32.
    Jahnsen J, Falch JA, Aadland E et al (1997) Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut 40:313–319PubMedGoogle Scholar
  33. 33.
    Dinca M, Fries W, Luisetto G et al (1999) Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol 94(5):1292–1297PubMedCrossRefGoogle Scholar
  34. 34.
    de Jong DJ, Corstens FH, Mannaerts L et al (2002) Corticosteroid-induced osteoporosis: does it occur in patients with Crohn’s disease? Am J Gastroenterol 97(8):2011–2015PubMedCrossRefGoogle Scholar
  35. 35.
    Dear KL, Compston JE, Hunter JO (2001) Treatments for Crohn’s disease that minimise steroid doses are associated with a reduced risk of osteoporosis. Clin Nutr 20(6):541–546PubMedCrossRefGoogle Scholar
  36. 36.
    Bernstein CN, Blanchard JF, Metge C (2003) The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 98(8):1797–1801PubMedCrossRefGoogle Scholar
  37. 37.
    Greenberg G, Feagan B, Martin F et al (1994) Oral budesonide for the treatment of active Crohn’s disease. N Engl J Med 331:836–841PubMedCrossRefGoogle Scholar
  38. 38.
    Manolagas SC, Jilka RL (1995) Bone marrow, cytokine and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332(5):305–311PubMedCrossRefGoogle Scholar
  39. 39.
    Andreassen H, Rungby J, Dahlerup F et al (1997) Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 32:1247–1255PubMedCrossRefGoogle Scholar
  40. 40.
    Lichtenstein GR (2003) Evaluation of bone mineral density in inflammatory bowel disease: current safety focus. Am J Gastroenterol 98(12):S24–S30PubMedCrossRefGoogle Scholar
  41. 41.
    Sambrook P, Birmingham J, Kelly P et al (1993) Prevention of corticosteroids osteoporosis: a comparison of calcium, calcitriol and calcitonin. N Engl J Med 328:1747–1752PubMedCrossRefGoogle Scholar
  42. 42.
    Bernstein CN, Seeger LL, Anton PA et al (1996) A randomized placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroids-using patients with IBD: a pilot study. Aliment Pharmacol Ther 10:777–786PubMedCrossRefGoogle Scholar
  43. 43.
    Cranney A, Welch V, Adachi JD et al (2001) Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev (4):CD003376Google Scholar
  44. 44.
    Nousari HC, Provost TT, Anhalt GJ (2001) Cutaneous manifestations of inflammatory bowel disease. In: Bayless TM, Hanauer SB (eds) Advanced therapy of inflammatory bowel disease. B.C. Becker, Hamilton, pp 271–274Google Scholar
  45. 45.
    Tromm A, May D, Almus E et al (2001) Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol 39:137–144PubMedCrossRefGoogle Scholar
  46. 46.
    Fleisher M, Rubin S, Levine A et al (2002) Infliximab in the treatment of refractory erythema nodosum of IBD. Gastroenterology 122(Suppl 1):A618Google Scholar
  47. 47.
    Bennet ML, Jackson JM, Jorizzo JL et al (2000) Pyoderma Gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine 79:37–46CrossRefGoogle Scholar
  48. 48.
    Wollina V (2002) Clinical management of pyoderma gangrenosum. Am J Clinical Dermatol 3:14–58Google Scholar
  49. 49.
    Hohenleutner U, Mohr VD, Michel S et al (1997) Mycophenolate mofetil and cyclosporine treatment for recalcitrant pyoderma gangrenosum. Lancet 350:1748PubMedCrossRefGoogle Scholar
  50. 50.
    D’Incà R, Fagiuoli S, Sturniolo GC (1998) Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Ann Intern Med 128:783–784PubMedGoogle Scholar
  51. 51.
    Regueiro M, Valentine J, Plevy S et al (2003) Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 98:1824–1826CrossRefGoogle Scholar
  52. 52.
    Brooklyn TN, Dunnill GS, Shetty A et al (2005) Infliximab for the treatment of pyoderma gangrenosum: a randomized, double-blind placebo controlled trial. Gut (Epub PMID:16188920)Google Scholar
  53. 53.
    Tavarela Veloso F (2004) Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 20(Suppl 4):50–53CrossRefGoogle Scholar
  54. 54.
    Fujimoto E, Fujimoto N, Kuroda K et al (2004) Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol 151:1090–1092PubMedCrossRefGoogle Scholar
  55. 55.
    Soukiasian S, Foster CS, Raizman MB (1994) Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol 118:601–611PubMedGoogle Scholar
  56. 56.
    Lamers CBHW (1997) Treatment of extraintestinal complication of ulcerative colitis. Eur J Gastroenterol Hepatol 9:850–853PubMedGoogle Scholar
  57. 57.
    Bargiggia S, Maconi G, Elli M et al (2003) Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clinical Gastroenterol 36(5):417–420CrossRefGoogle Scholar
  58. 58.
    Hutchinson R, Tyrrel PN, Kumar D et al (1994) Pathogenesis of gallstones in Crohn’s disease: an alternative explanation. Gut 35(1):94–97PubMedGoogle Scholar
  59. 59.
    Wiesner RH (1994) Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 69:969–982PubMedGoogle Scholar
  60. 60.
    Spurkland A, Saarinen S, Boberg KM et al (1999) HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 53:459–69PubMedCrossRefGoogle Scholar
  61. 61.
    Grant AJ, Lalor PF, Salmi M et al (2002) Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359:150–157PubMedCrossRefGoogle Scholar
  62. 62.
    Spirli C, Fabris L, Duner E et al (2003) Cytokine-stimulated nitric oxide production inhibits adenyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 124:737–753PubMedCrossRefGoogle Scholar
  63. 63.
    Cullen SN, Chapman RW (2005) Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 21:933–948PubMedCrossRefGoogle Scholar
  64. 64.
    Beuers U, Spengler U, Kruis W et al (1992) Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepathology 16:707–714Google Scholar
  65. 65.
    Stiehl A, Walker S, Sthiel L et al (1994) Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 20:57–64PubMedCrossRefGoogle Scholar
  66. 66.
    Mitchell SA, Bansi DS, Hunt N et al (2001) A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121:900–907PubMedCrossRefGoogle Scholar
  67. 67.
    Buurgert SL, Brown BP, Kirkpatrick RB (1984) Positive corticosteroid response in early primary sclerosing cholangitis (abstract). Gastroenterology 86:1037(A)Google Scholar
  68. 68.
    Lindor KD, Wiesner RH, Colwell LJ et al (1991) The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 86:57–61PubMedGoogle Scholar
  69. 69.
    Knox TA, Kaplan MM (1991) Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 86:546–552PubMedGoogle Scholar
  70. 70.
    Knox TA, Kaplan MM (1994) A double-blind controlled trial of oral pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 106:494–499PubMedGoogle Scholar
  71. 71.
    Lindor KD, Jorgensen RA, Anderson ML et al (1996) Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 91:511–515PubMedGoogle Scholar
  72. 72.
    Talwalkar JA, Lindor KD (2005) Primary sclerosing cholangitis. Inflamm Bowel Disease 11(1):62–72CrossRefGoogle Scholar
  73. 73.
    Bharucha AE, Jorgensen R, Lichtman SN et al (2000) A pilot study of pentoxifylline for the treatment primary sclerosing cholangitis. Am J Gatroenterol 95:2338–2342CrossRefGoogle Scholar
  74. 74.
    Epstein MP, Kaplan MM (2004) A pilot study of etanercept in the treatment primary sclerosing cholangitis. Dig Dis Sci 49:1–4PubMedCrossRefGoogle Scholar
  75. 75.
    Moayyeri A, Daryani NE, Barhami H et al (2005) Clinical course of ulcerative colitis in patients with or without primary sclerosing cholangitis. J Hepatol Gastroenterol 20:366–370CrossRefGoogle Scholar
  76. 76.
    Gorgun E, Remzi FH, Manilich E et al (2005) Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case control study. Surgery 138(4):631–637PubMedCrossRefGoogle Scholar
  77. 77.
    Chambers WM, Warren BF, Jewell DP et al (2005) Cancer surveillance in ulcerative colitis. Br J Surg 92(8):928–936PubMedCrossRefGoogle Scholar
  78. 78.
    Broome U, Lindberg G, Lofberg R (1992) Primary sclerosing-cholangitis in ulcerative colitis: a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 102(6):1877–1880PubMedGoogle Scholar
  79. 79.
    Pardi DS, Loftus EV, Kremers WK et al (2003) Ursodeoxycholic acid acts as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124:889–893PubMedCrossRefGoogle Scholar
  80. 80.
    Wolf JM, Rybicki LA, Lashner BA (2005) The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 22:783–788PubMedCrossRefGoogle Scholar
  81. 81.
    Haagsma EB, Van Den Berg AP, Kleinbeuker JH et al (2003) Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther 18(1):33–44PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Giacomo C. Sturniolo
    • 1
  • Michela Barollo
    • 1
  • Renata D’Incà
    • 1
  1. 1.Department of GastroenterologyUniversity of PaduaPaduaItaly

Personalised recommendations